Matt Hoffman

Marketed as Amvuttra, the Alnylam Pharmaceuticals RNA-interference treatment is now approved for an additional patient population of 150,000 in the US, and more than 300,000 worldwide.

Data from more than 16,000 trial participants point to possible challenges with assessing and safely administering novel therapeutics among those with comorbidities—which may be present in as much as half of the patient population.

The thrombolytic treatment, branded as TNKase and approved for adults, is administered as a 5-second IV bolus, upping the speed and simplicity of the 60-minute infusion of the previously approved alteplase (Activase; Genentech).

With new revisions of the MS diagnostic criteria being made, clinicians highlighted key updates and the broader implications it has for diagnosis, treatment, and healthcare practices worldwide.

When looking at the intersection of MS and domestic abuse, one can find hidden challenges and a need for innovative efforts to support vulnerable patients and survivors.

The positive finding on the secondary end point of 6-month confirmed disability worsening supports the data from the phase 3 HERCULES trial in secondary progressive multiple sclerosis.

Nicole M. Boschi, PhD, the director of regulatory affairs at the National MS Society, talked about the impact of the upcoming Medicare Part D and Medicare Advantage changes for the multiple sclerosis community.

The codirector of the Precision Medicine MS Center at Johns Hopkins University discussed the new updates to the MS diagnostic criteria presented at the 40th ECTRIMS Congress in Copenhagen. [WATCH TIME: 5 minutes]

Data from the MAGNIFY-MS study suggest that low 24-month PIRA rates across age groups and among those with or without treatment experience.

The data showed only a small number of infusion-related reactions among patients with MS transitioning from other disease-modifying therapies.

Researchers detected annual changes in patients with preataxic and early ataxic spinocerebellar ataxia in brain MRI imaging, clinical scores, gait parameters, and retinal thickness.

Marketed as Crexont, the combination extended- and immediate-release treatment is indicated for treatment of PD, and is anticipated to be available in the United States in September 2024.

The trial will use phase 2a to determine the optimal dosage while phase 2b will assess efficacy and long-term safety of the optimized dose against a placebo arm.

The drug showed a strong safety profile and met primary endpoints, showing efficacy in slowing clinical and biological decline and supporting further investigation in a phase 2/3 trial.

Marketed as Zunveyl for mild-to-moderate Alzheimer disease, ALPHA-1062 is considered a new-generation acetylcholinesterase inhibitor with expected minimal gastrointestinal adverse events.

The expanded indication, supported by a phase 2 open-label trial, includes children of all ages with CLN2 disease, regardless of whether they are symptomatic or asymptomatic.

With the approved IND, it expands research efforts of equecabtagene autoleucel from other autoimmune conditions like myasthenia gravis and NMOSD.

Secondary symptoms of PD can be as debilitating as the primary motor symptoms, often leading to increased disability, reduced independence, and a higher burden on caregivers.

Brivaracetam was largely well tolerated and shown to be effective for a proportion of patients with intellectual disability, indicated by similar responses across different levels of intellectual disability severity.

The neurologist and assistant professor at Boston University Medical Center provided forward thoughts on improving the diagnosis of milder, asymptomatic cases of cerebral amyloid angiopathy. [WATCH TIME: 4 minutes]

The AAV vector-based gene therapy originally received FDA approval for treating ambulatory pediatric patients aged 4 to 5 years with Duchenne under the accelerated approval pathway.

Following presented phase 1 clinical trial findings at AAN 2024, bemdaneprocel receives regenerative medicine advanced therapy designation by the FDA for the treatment of Parkinson disease.

The headset features soft-tip electrodes, artificial intelligence-enabled notifications, and cloud integration for remote monitoring of EEG in clinical practice.

According to recent studies and the latest insights provided by experts, early developments in gene and cell therapies show promise for patients living with Parkinson disease, but challenges remain.

The FDA approval of the increased maximum daily dose for amifampridine offers clinicians and patients greater flexibility in treatment regimens for the management of Lambert-Eaton myasthenic syndrome.

Known for his expertise in stem cell transplantation, Cleveland Clinic researcher Jeffrey Cohen, MD, shifted gears to discuss other cell-based therapies in his Whitaker Lecture at the CMSC Annual Meeting.

CMSC speakers discussed how AI technologies, for better or worse, are beginning to shape the management of MS.

Florida-based neurologist Donal Negroski, MD, presents data from an aging MS patient population looking for treatment options under Medicare.

Fred Lublin, MD, the CMSC Presidential Lecture speaker, offers updated views on how to define MS clinical progression.

MS does not carry an increased risk of high-risk pregnancy, but many clinicians are unclear about best practices for managing these patients.